Moleculin Biotech Inc buy melinda
Summary
This prediction ended on 27.06.17 with a price of €11.15. The BUY prediction by melinda finished with a performance of 1.28%. melinda has 50% into this predictionMoleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Moleculin Biotech Inc | - | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
Comments by melinda for this prediction
In the thread Moleculin Biotech Inc diskutieren
Biotech
Moleculin ad wissenschaftliche Unterstützung für Forschungsanstrengungen an der Mayo Clinic
HOUSTON, TX - (MARKET - 26. Juni 2017) - Moleculin Biotech, Inc. (NASDAQ: MBRX ) ( "Moleculin" oder das "Unternehmen"), ein vorklinischen pharmazeutischen Unternehmen , das sich auf die Entwicklung von Kandidaten für Krebsmedikamente, einige basierte auf Lizenzvereinbarungen mit der Universität of Texas System im Namen des MD Anderson Cancer Center, gab heute bekannt , dass es eine Vereinbarung mit einem Arzt an der Mayo Clinic erreichte am Moleküle WP1066 zusätzliche Forschung zu ermöglichen , Moleculin für die mögliche Behandlung einer seltenen Form von pädiatrischen Hirntumor.
Stopped prediction by melinda for Moleculin Biotech Inc
Moleculin Biotech Inc
15.07.20
04.11.21
05.11.21
Moleculin Biotech Inc
21.04.19
22.04.19
22.04.19
Moleculin Biotech Inc
30.08.18
23.01.19
23.01.19
Moleculin Biotech Inc
28.02.18
28.08.18
28.08.18
Moleculin Biotech Inc
29.06.17
19.12.17
19.12.17
Moleculin Biotech Inc
29.06.17
19.12.17
19.12.17
Moleculin Biotech Inc
22.06.17
27.06.17
27.06.17